Myostatin: A Powerful Biomarker for Sarcopenia and Frailty?

Laurent, Michaël; Dupont, Jolan; Dejaeger, Marian; Gielen, Evelien

doi:10.1159/000495839

Cited by 9 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have proposed the use of serum myostatin as a predictive marker for the early diagnosis of sarcopenia and other forms of muscle wasting associated with aging. 65 , 66 ) One study reported higher serum insulin-like growth factor 1 (IGF-1) levels in older adults with SO who performed weight training compared to those in the SO group that did not perform weight training. These findings provided evidence that a deficit in IGF-1 increased the risk of developing SO.…”

Section: Prevalence Of Sarcopenic Obesitymentioning

confidence: 99%

Prevalence of Sarcopenic Obesity in Various Comorbidities, Diagnostic Markers, and Therapeutic Approaches: A Review

Kumari

Khanna

2022

Ann Geriatr Med Res

View full text Add to dashboard Cite

The coexistence of sarcopenia and obesity characterizes sarcopenic obesity. In this condition, there is an imbalance between lean and fat mass amounts. It is a prevalent issue that is gaining prevalence among the elderly population. To evaluate the condition, allied health professionals may employ non-invasive diagnostic techniques, such as gait speed, skeletal muscle mass, and muscle strength. Nevertheless, early diagnosis and treatment of pathology are essential for preventing debilitating effects and providing the highest quality of care. This article reviews the prevalence of sarcopenic obesity in numerous medical conditions, such as cancer, arthritis, postoperative cases, diabetes mellitus, obesity, and metabolic syndrome. In addition, this paper aims to examine the available evidence regarding the prevalence of sarcopenic obesity in other conditions along with their diagnostic markers and therapeutic approaches.

show abstract

Section: Prevalence Of Sarcopenic Obesitymentioning

confidence: 99%

Prevalence of Sarcopenic Obesity in Various Comorbidities, Diagnostic Markers, and Therapeutic Approaches: A Review

Kumari

Khanna

2022

Ann Geriatr Med Res

View full text Add to dashboard Cite

show abstract

“…Despite not being a feasible biomarker in isolation, a recent review concluded that MSTN could be a valuable contributor to a recently suggested panel of muscle wasting biomarkers [ 109 ]. Moreover, Laurent et al [ 110 ] in a letter to the editor raised concerns that sarcopenia and frailty often appear together but are separate disorders and asserted that there must be a clearer correlation between MSTN and each condition separately. A second claim has been made that MSTN’s influence on circulating versus autocrine/local hormones needs to be better understood [ 110 ].…”

Section: Risk Factors For Sarcopeniamentioning

confidence: 99%

“…Moreover, Laurent et al [ 110 ] in a letter to the editor raised concerns that sarcopenia and frailty often appear together but are separate disorders and asserted that there must be a clearer correlation between MSTN and each condition separately. A second claim has been made that MSTN’s influence on circulating versus autocrine/local hormones needs to be better understood [ 110 ]. Activin A and B , are members of the transforming growth factors (TGF)β superfamily and may have an important role in regulating muscle mass.…”

Section: Risk Factors For Sarcopeniamentioning

confidence: 99%

A Multifactorial Approach for Sarcopenia Assessment: A Literature Review

Supriya

Singh

et al. 2021

Biology

View full text Add to dashboard Cite

Sarcopenia refers to a progressive and generalized weakness of skeletal muscle as individuals age. Sarcopenia usually occurs after the age of 60 years and is associated with a persistent decline in muscle strength, function, and quality. A comparison of the risk factors associated with sarcopenia based on the European Working Group on Sarcopenia (1 and 2) in Older People, the Asian Working Group for Sarcopenia (1 and 2), the International Working Group on Sarcopenia, and the Foundation for the National Institutes of Health revealed no consistent patterns. Accordingly, the identification of a single risk factor for sarcopenia is unpredictable due to its “multifactorial” pathogenesis, with the involvement of a multitude of factors. Therefore, the first aim of this review was to outline and propose that the multiple factors associated with sarcopenia need to be considered in combination in the design of new experimentation in this area. A secondary aim was to highlight the biochemical risk factors that are already identified in subjects with sarcopenia to assist scientists in understanding the biology of the pathophysiological mechanisms affecting the old people with sarcopenia. We also briefly discuss primary outcomes (physical) and secondary outcomes (social and financial) of sarcopenia. For future investigative purposes, this comprehensive review may be useful in considering important risk factors in the utilization of a panel of biomarkers emanating from all pathways involved in the pathogenesis of this disease. This may help to establish a uniform consensus for screening and defining this disease. Considering the COVID-19 pandemic, its impact may be exacerbated in older populations, which requires immediate attention. Here, we briefly suggest strategies for advancing the development of smart technologies to deliver exercise in the COVID-19 era in an attempt regress the onset of sarcopenia. These strategies may also have an impact on sarcopenia’s primary and secondary outcomes.

show abstract

“…В этой связи представляется актуальным анализ и обобщение результатов работ, посвященных изучению биологической роли и клиническому значению миостатина. Исследования в данном направлении имеют важное значение не только в области диагностики, но и терапии ряда социально значимых заболеваний [5].…”

Section: Abstract: Myostatin Cachexia Cancer Chronic Heart Failureunclassified

Modern conception of myostatin biological role and clinical significance as the main regulator of muscle growth and differentiation

Кукес¹,

Gazdanova²,

Furalev³

et al. 2021

Medical news of the North Caucasus

View full text Add to dashboard Cite

Myostatin: A Powerful Biomarker for Sarcopenia and Frailty?

Cited by 9 publications

References 10 publications

Prevalence of Sarcopenic Obesity in Various Comorbidities, Diagnostic Markers, and Therapeutic Approaches: A Review

Prevalence of Sarcopenic Obesity in Various Comorbidities, Diagnostic Markers, and Therapeutic Approaches: A Review

A Multifactorial Approach for Sarcopenia Assessment: A Literature Review

Modern conception of myostatin biological role and clinical significance as the main regulator of muscle growth and differentiation

Contact Info

Product

Resources

About